Evidence map›Paper›PMID 41411622›Full record

ArticleCancer research2026

Integrated Spatial Analysis Reveals the Molecular Landscape of Ovarian Precancerous Lesions.

Tu-Yung Chang, Yen-Wei Chien, Szu-Hua Chen, Annelise Sokolow, Yeh Wang, Brant G Wang, Tricia A Numan, M Herman Chui, Rebecca L Stone, Thomas R Pisanic and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Tubal epithelial alterations: evolving concepts.Journal of gynecologic oncology · 2026
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Tu-Yung ChangDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0009-0007-8589-7775
Yen-Wei ChienDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0009-0003-4202-6735
Szu-Hua ChenDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0003-0756-6317
Annelise SokolowDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0009-0007-4461-3123
Yeh WangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0003-3185-4802
Brant G WangDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-1329-1586
Tricia A NumanDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-2855-0867
M Herman ChuiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York.ORCID 0000-0002-7220-3996
Rebecca L StoneDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0003-3590-5152
Thomas R PisanicInstitute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-5796-0836
Nickolas PapadopoulosSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0001-7135-7451
Tian-Li WangDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0002-7082-449X
Christopher DouvilleSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0002-2510-4151
Leslie CopeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0002-4098-3289
Ie-Ming ShihDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0000-0002-1084-2071

Funding

SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Amanda Nickles Fader · 2018 to 2026
$20.5M
Biomarker Reference LaboratoryU2CCA271891 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHEN ZHANG · 2022 to 2026
$4.0M
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk womenR01CA260628 · NCI · JOHNS HOPKINS UNIVERSITY · PI PISANIC II, THOMAS RUSSELL, SHIH, IE-MING · 2021 to 2025
$2.1M
Experimental Therapeutics by targeting Spleen Tyrosine KinaseR01CA215483 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING · 2017 to 2021
$1.9M
Break Through Cancer (BTC) IOCHonorable Tina Brozman Foundation (TW) 145399National Institutes of Health (NIH) P50CA228991National Institutes of Health (NIH) R01CA215483National Institutes of Health (NIH) R01CA260628National Institutes of Health (NIH) U2CCA271891NCI NIH HHS P50 CA228991NCI NIH HHS U2C CA271891
6 · The paper itself

Abstract

Studying precancerous lesions is essential for improving early detection and prevention, particularly in aggressive cancers such as ovarian carcinoma. In this study, we conducted integrated and spatial analyses of transcriptomes, aneuploidy, and clinicopathologic features in 166 ovarian precancerous lesions. Four precancerous transcriptomic subtypes were identified: proliferative, immunoreactive, dormant, and mixed. These subtypes varied in their frequency of germline BRCA1/2 mutations, aneuploidy, CCNE1/MYC amplification, proliferative activity, immunoregulatory gene expression, and histologic features. Notably, the immunoreactive subtype upregulated immunoregulatory genes, exhibited chronic inflammation, and was enriched in cases with germline BRCA1/2 mutations and deletions of chromosomes 17 (harboring TP53 and BRCA1) and 13 (harboring BRCA2), leading to a double "two-hit" involving TP53 and BRCA1/2. Tumor invasion was associated with the activation of interferon response pathways, epithelial-mesenchymal transition, and extracellular matrix remodeling. In summary, these results elucidate the earliest molecular landscape of ovarian precancerous lesions, serving as the foundation for future risk stratification to identify aggressive precancerous lesions. SIGNIFICANCE: Integrated spatial multiomics analysis of ovarian precancerous lesions reveals molecular subtypes and mechanisms underlying tumor initiation, offering a foundation for future risk stratification and prevention. See related commnetary by Soong et al. p. 1537.

Indexed as

Biomarkers, TumorOvarian NeoplasmsPrecancerous ConditionsAdultAneuploidyBRCA1 ProteinBRCA2 ProteinFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGerm-Line MutationHumansMiddle AgedTranscriptomeBiomarkers, TumorBRCA1 ProteinBRCA2 Protein

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.